# mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line

> **NCT03464968** · PHASE2 · COMPLETED · sponsor: **Seoul National University Bundang Hospital** · enrollment: 120 (actual)

## Conditions studied

- Biliary Cancer Metastatic

## Interventions

- **DRUG:** Oxaliplatin,5FU, leucovorin
- **DRUG:** irinotecan,5FU, leucovorin

## Key facts

- **NCT ID:** NCT03464968
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-29
- **Primary completion:** 2020-02-10
- **Final completion:** 2020-07-25
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2020-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03464968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03464968, "mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03464968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*